Evidence map›Paper›PMID 32171811›Full record

ArticleJournal of the American Academy of Dermatology2021

Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.

Joseph R Stoll, Toral S Vaidya, Shoko Mori, Stephen W Dusza, Mario E Lacouture, Alina Markova

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Academy of Dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.International journal of hematology-oncology and stem cell research · 2022
    Review
  7. Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.International journal of molecular sciences · 2020
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Joseph R StollDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Toral S VaidyaDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Shoko MoriDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Stephen W DuszaDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Mario E LacoutureDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Weill Cornell Medical College, New York, New York.
Alina MarkovaDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Weill Cornell Medical College, New York, New York. Electronic address: markovaa@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundSevere cutaneous adverse reactions (SCARs) are associated with high morbidity and mortality in patients with cancer. Early identification and treatment of SCARs may improve outcomes.

objectiveTo identify biomarkers to predict outcomes in hospitalized patients with cancer who developed SCARs.

methodsRetrospective review of 144 hospitalized patients with cancer with a morbilliform rash, recorded testing for serum cytokines (interleukin [IL]-6, IL-10, and tumor necrosis factor [TNF]-α) or elafin, and a dermatology consultation. Rashes were categorized as simple morbilliform rash without systemic involvement or complex morbilliform rash with systemic involvement.

resultsFifty-four of 144 (37.5%) patients died during follow-up. Elevated levels of IL-6, IL-10, and TNF-α were associated with decreased survival. Overall survivals in patients with elevated levels of IL-6, IL-10, and TNF-α were 53.7%, 56.6%, 53.6%, respectively, compared with 85.7%, 82.5% and 83.6%, respectively, in those with lower levels. Patients with increased levels of both IL-6 and TNF-α had a nearly 6-fold increase in mortality (hazard ratio, 5.82) compared with patients with lower levels. LIMITATIONS: Retrospective design, limited sample size, and high-risk population.

conclusionsHospitalized patients with cancer with rash and elevated IL-6 and TNF-α were nearly 6 times more likely to die over the course of follow-up. These biomarkers may serve as prognostic biomarkers and therapeutic targets for this high-risk population.

Indexed as

Antineoplastic AgentsBiomarkers, TumorDrug EruptionsFemaleFollow-Up StudiesHospital MortalityHumansInterleukin-10Interleukin-6Kaplan-Meier EstimateMaleMiddle AgedNeoplasmsPrognosisRetrospective StudiesRisk AssessmentAntineoplastic AgentsBiomarkers, TumorIL10 protein, humanIL6 protein, humanInterleukin-10Interleukin-6TNF protein, humanTumor Necrosis Factor-alphabiomarkercytokinedrug-induced hypersensitivity syndromedrug rashdrug reactiondrug reaction with eosinophilia and systemic symptomsgraft-versus-host diseaseinterleukin-6 (IL-6)mortalitysevere cutaneous adverse reactionsurvivaltumor necrosis factor alpha (TNF-α)

Identifiers

PMID32171811
PMCPMC7486231
OpenAlexW3011084325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.